Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13085
Full metadata record
DC FieldValueLanguage
dc.contributor.authorO'Callaghan, Christopher Jen
dc.contributor.authorKrum, Henryen
dc.contributor.authorConway, Elizabeth Len
dc.contributor.authorLam, Wen
dc.contributor.authorSkiba, M Aen
dc.contributor.authorHowes, L Gen
dc.contributor.authorLouis, William Jen
dc.date.accessioned2015-05-16T02:51:57Z
dc.date.available2015-05-16T02:51:57Z
dc.date.issued1994-11-01en
dc.identifier.citationBlood Pressure; 3(6): 404-6en
dc.identifier.govdoc7704289en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13085en
dc.description.abstractIn this study, which was primarily designed to determine the lipid-lowering efficacy of pravastatin in the setting of background antihypertensive therapy with ACE inhibitors and calcium antagonists, we took the opportunity to examine whether pravastatin interacts with antihypertensive therapy to produce additional falls in blood pressure. This may help clarify the mechanism of action of pravastatin's rapid beneficial effects on cardiovascular morbidity. We treated 25 hypertensive hypercholesterolaemic patients with 12 weeks of either pravastatin or placebo in this double blind, placebo controlled parallel group study. Placebo treatment did not alter plasma lipids, whereas 12 weeks' treatment with pravastatin reduced total cholesterol by 27% (from 7.1 +/- 0.27 to 5.2 +/- 0.18, p < 0.001 compared with placebo) and low density lipoprotein cholesterol by 35% (from 4.9 +/- 0.36 to 3.2 +/- 0.17, p < 0.001). There were no changes in systolic or diastolic blood pressure either following 12 weeks' treatment or 3 weeks' withdrawal of pravastatin. Thus, pravastatin remains efficacious as a lipid lowering agent in the presence of antihypertensive therapy but does not enhance the blood pressure lowering action of these drugs. Therefore it is unlikely that blood pressure reduction is the mechanism by which pravastatin mediates its reported short term effects on cardiovascular morbidity.en
dc.language.isoenen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCaptopril.pharmacology.therapeutic useen
dc.subject.otherCholesterol.blooden
dc.subject.otherCholesterol, LDL.blooden
dc.subject.otherCombined Modality Therapyen
dc.subject.otherDouble-Blind Methoden
dc.subject.otherDrug Interactionsen
dc.subject.otherFelodipine.pharmacology.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherHypercholesterolemia.blood.complications.diet therapy.drug therapy.physiopathologyen
dc.subject.otherHypertension.blood.complications.drug therapy.physiopathologyen
dc.subject.otherLipids.blooden
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPravastatin.pharmacology.therapeutic useen
dc.titleShort term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients.en
dc.typeJournal Articleen
dc.identifier.journaltitleBlood pressureen
dc.identifier.affiliationHypertension Services, Austin Hospital, Heidelberg, Australiaen
dc.description.pages404-6en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/7704289en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.